Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pediatric advisory committee considers heartburn drugs

This article was originally published in The Tan Sheet

Executive Summary

FDA's Pediatric Advisory Committee will meet June 21 in Bethesda, Md., to discuss pediatric safety reviews for several drugs, including proton pump inhibitors Prevacid (lansoprazole) and Prilosec (omeprazole), according to a May 11 Federal Register notice. The notice does not specify if the drugs could be available to children in the future, but currently both products are recommended for patients 18 years and older. Comments are due June 7

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS104121

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel